# Hidradenitis Suppurativa Market

> Hidradenitis Suppurativa Market Research Report: Size, Share, Trend Analysis By Skin Conditions (Pimples, Folliculitis, Deep-acne like cysts & blackheads, and Boils), By Treatment (Medications and Surgery) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.72%
- **2024:** $ 0.66 Billion
- **2025:** $ 0.69 Billion
- **2035:** $ 1.1 Billion
- **Key Players:** AbbVie (US), Amgen (US), Janssen Pharmaceuticals (US), Novartis (CH), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GSK (GB), Sanofi (FR), Pfizer (US) — key contributors to the expanding hidradenitis suppurativa therapeutics market landscape.

**Report ID:** MRFR/Pharma/2497-HCR · **Pages:** 68 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/hidradenitis-suppurativa-market-3770

---

## Market Summary

## **Hidradenitis Suppurativa Market Overview**

Hidradenitis Suppurativa Market Size was valued at USD 0.63 Billion in 2023. The Hidradenitis Suppurativa market industry is projected to grow from USD 0.66 Billion in 2024 to USD 0.96 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.72% during the forecast period (2024 - 2032).Increased funding for healthcare infrastructure, rising activities by public and commercial organisations to raise awareness, rising rates of obesity, and an increase in the frequency of skin diseases are all contributing factors, are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Hidradenitis Suppurativa Market Trends**

According to forecasts made by industry insiders for the current forecast period, which will end in 2028, the market for hidradenitis suppurativa is projected to thrive with rising incidences of many skin illnesses. The FDA is approving clinical trial and drug processes, which is assisting in the growth and expansion of the worldwide hidradenitis suppurativa market.

The market is also anticipated to grow as new medicine and treatment trends are introduced, along with an increase in understanding about skin conditions and other healthcare issues. environmental changes including pollution and ozone layer depletion have been made worse by the rising degree of warming in all parts of the earth. Additionally, this is significantly affecting the target market's skin globally, which is driving the market expansion for hidradenitis suppurativa throughout the assessment period of 2017–2023.

The increasing cost of healthcare contributes to the development of the market for hidradenitis suppurativa and has a substantial impact on its growth rate. The market for hidradenitis suppurativa will also grow as a result of expanding awareness-raising campaigns by both public and private organisations and an increase in obesity incidence. Additionally, the market for hidradenitis suppurativa will grow as a result of increased disposable income and changing lifestyles of individuals. Along with this, an ageing population and an increase in smoking rates will accelerate the market's rise.

Furthermore, one of the main factors fueling market expansion (UI) is the rise in the prevalence of skin illnesses. In addition, secondary infections, hair follicle obstructions, and irritation of specific sweat glands all support the growth of the hidradenitis suppurativa market. Thus, driving the Hidradenitis Suppurativa market revenue.

## **Hidradenitis Suppurativa Market Segment Insights**

### **Hidradenitis Suppurativa Skin Conditions Insights**

The Hidradenitis Suppurativa market segmentation, based on Skin Conditions includes Pimples, Folliculitis, Deep-acne like cysts & blackheads, and Boils. The market was dominated by the deep-acne like cysts and blackheads category, which generated 29% of market revenue (0.09 billion). EGF is a very powerful [acne treatment](../../../reports/acne-treatment-market-5675), especially when used in place of harsher drugs like retinol, which also accelerate cellular turnover.

### **Hidradenitis Suppurativa Treatment Insights**

The Hidradenitis Suppurativa market segmentation, based on treatment, includes Medications and Surgery. The category of medications produced the largest revenue (68.4%). Antibiotics, biologics, retinoids, corticosteroids, and hormone therapy are among the drugs used to treat Hidradenitis Suppurativa (HS).

**Figure 1: Hidradenitis Suppurativa Market, by Treatment, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

### **Hidradenitis Suppurativa Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Hidradenitis Suppurativa Market dominated this market in 2022 (45.80%). In North America, the prevalence of HS ranges from 0.1% to 2%, with a preference for individuals in their third and fourth decades of life. The aetiology of HS is unknown, but both genetic and environmental factors are linked to the condition. The main symptom of the illness is a blockage of the hair follicles, which can result in the development of nodules, abscesses, and tunnels under the skin.

Further, the U.S. Hidradenitis Suppurativa market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: HIDRADENITIS SUPPURATIVA MARKET SHARE BY REGION 2022 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

Europe Hidradenitis Suppurativa market accounts for the second-largest market share. This is because medical therapy, which may include antibiotics, acitretin, and biologics like adalimumab and infliximab, is recommended by the European S1 guideline for the treatment of HS. Further, the German Hidradenitis Suppurativa market held the largest market share, and the UK Hidradenitis Suppurativa market was the fastest growing market in the European region

The Asia-Pacific Hidradenitis Suppurativa Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because inflammatory skin diseases are becoming more common, healthcare knowledge and government support are increasing, there are more generic manufacturers, and there are more government initiatives in this area. Moreover, China’s Hidradenitis Suppurativa market held the largest market share, and the Indian Hidradenitis Suppurativa market was the fastest growing market in the Asia-Pacific region.

**Hidradenitis Suppurativa Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Hidradenitis Suppurativa market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Hidradenitis Suppurativa industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Hidradenitis Suppurativa industry to benefit clients and increase the market sector. In recent years, the Hidradenitis Suppurativa industry has offered some of the most significant advantages to medicine. Major players in the Hidradenitis Suppurativa market, including AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US) and others, are attempting to increase market demand by investing in research and development operations.

Two German businessmen named Charles Pfizer and Charles F. Erhart founded the worldwide pharmaceutical and biotechnology company Pfizer in 1849 in New York. The business's main office is in Manhattan, New York City. Pfizer is a top biopharmaceutical firm with a strong focus on research. It uses science and resources to develop medications that help people live longer and significantly better lives. Medicines, vaccines, and many of the most well-known consumer healthcare goods are all part of the company's portfolio.

Pfizer's dedication to ESG covers a variety of areas, including product innovation, fair access to and pricing of products, product quality and safety, diversity, fairness, and inclusion, and climate change. The business has acquired a number of businesses, including Amplyx Pharmaceuticals and the fosmanogepix antifungal drug. In addition, Pfizer was fined $3 billion as a consequence of criminal convictions, civil penalties, and jury awards for engaging in dishonest marketing practises, paying off doctors, and hiding negative trial outcomes.

AstraZeneca is a multi-national, science-driven biopharmaceutical company that creates, produces, and markets drugs and biotechnology for the treatment of diseases related to oncology, the cardiovascular system, the gastrointestinal tract, and the respiratory system. Millions of patients throughout the world use the company's cutting-edge medications. The mission and values of AstraZeneca include adhering to research and prioritising patients. In addition to pioneering an oncology revolution to rethink cancer care for the millions of people living with cancer, the company has a portfolio of therapies for key diseases.

The FDA has not yet given the corporation permission to use the vaccine in an emergency situation in the US.

**Key Companies in the Hidradenitis Suppurativa market include**

### Hidradenitis Suppurativa Market Industry Developments

- **Q2 2024: UCB receives FDA approval for BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults** UCB announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX® (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa, marking a significant regulatory milestone for the company’s dermatology portfolio.
- **Q2 2024: Novartis receives European Commission approval for Cosentyx® (secukinumab) for the treatment of hidradenitis suppurativa** Novartis announced that the European Commission approved Cosentyx® (secukinumab) for the treatment of active moderate to severe hidradenitis suppurativa in adults, expanding the drug’s indications in the EU.
- **Q2 2024: AbbVie announces positive Phase 3 results for SKYRIZI® (risankizumab) in hidradenitis suppurativa** AbbVie reported that its Phase 3 clinical trial of SKYRIZI® (risankizumab) in patients with moderate to severe hidradenitis suppurativa met its primary endpoints, supporting future regulatory submissions.
- **Q1 2024: UCB submits Marketing Authorization Application to EMA for bimekizumab for hidradenitis suppurativa** UCB announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for bimekizumab for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q3 2024: Novartis announces FDA acceptance of sBLA for Cosentyx® in hidradenitis suppurativa** Novartis announced that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for Cosentyx® (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q2 2024: InflaRx announces positive topline results from Phase III trial of vilobelimab in hidradenitis suppurativa** InflaRx reported positive topline results from its Phase III trial evaluating vilobelimab in patients with moderate to severe hidradenitis suppurativa, supporting further regulatory discussions.
- **Q2 2024: MoonLake Immunotherapeutics announces positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa** MoonLake Immunotherapeutics announced that its Phase 2 MIRA trial of sonelokimab in moderate to severe hidradenitis suppurativa met its primary and key secondary endpoints.
- **Q1 2024: InflaRx receives FDA Fast Track designation for vilobelimab in hidradenitis suppurativa** InflaRx announced that the U.S. FDA granted Fast Track designation to vilobelimab for the treatment of hidradenitis suppurativa, expediting its development and review.
- **Q2 2024: UCB launches BIMZELX® (bimekizumab) in the U.S. for hidradenitis suppurativa** Following FDA approval, UCB announced the commercial launch of BIMZELX® (bimekizumab) in the United States for adults with moderate to severe hidradenitis suppurativa.
- **Q2 2024: MoonLake Immunotherapeutics raises $400 million in public offering to advance sonelokimab for hidradenitis suppurativa** MoonLake Immunotherapeutics completed a $400 million public offering to fund the continued development and potential commercialization of sonelokimab for hidradenitis suppurativa.

## **Hidradenitis Suppurativa Market Segmentation**

### **Hidradenitis Suppurativa Skin Conditions Outlook**

### **Hidradenitis Suppurativa Treatment Outlook**

### **Hidradenitis Suppurativa Regional Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The upward trend in healthcare expenditure is a significant driver for the Hidradenitis Suppurativa Market. As countries allocate more resources to healthcare, there is an increased focus on chronic conditions like HS, which require long-term management and treatment. This financial commitment is likely to enhance access to advanced therapies and improve patient outcomes. Reports indicate that healthcare spending is expected to rise by approximately 5% annually, which could translate into greater investment in dermatological conditions. Consequently, pharmaceutical companies may be incentivized to develop and market new treatments for HS, thereby expanding the Hidradenitis Suppurativa Market. This financial landscape suggests a promising future for both patients and providers as more resources become available for managing this challenging condition.

### Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the Hidradenitis Suppurativa Market. The introduction of biologic therapies, such as adalimumab and infliximab, has transformed the management of HS, offering new hope for patients with moderate to severe forms of the disease. These treatments target specific pathways in the inflammatory process, leading to improved outcomes. The market for biologics is projected to grow substantially, with estimates indicating a compound annual growth rate (CAGR) of over 10% in the coming years. Additionally, the development of novel therapies, including small molecules and gene therapies, is on the horizon, which may further enhance treatment options. As these advancements continue to emerge, the Hidradenitis Suppurativa Market is likely to experience a surge in investment and research, fostering a more robust therapeutic landscape.

### Integration of Telemedicine in Dermatology

The integration of telemedicine into dermatological practices is emerging as a transformative factor in the Hidradenitis Suppurativa Market. Telehealth services facilitate remote consultations, enabling patients to access specialized care without geographical constraints. This is particularly beneficial for individuals with HS, who may experience discomfort or mobility issues. The convenience of telemedicine is likely to encourage more patients to seek treatment, thereby increasing market demand. Furthermore, the use of digital platforms for monitoring and managing HS can enhance patient engagement and adherence to treatment plans. As telemedicine continues to gain traction, it may reshape the landscape of dermatological care, potentially leading to a more efficient and patient-centered approach in the Hidradenitis Suppurativa Market.

### Growing Patient Advocacy and Support Groups

The emergence of patient advocacy and support groups is playing a crucial role in shaping the Hidradenitis Suppurativa Market. These organizations are dedicated to raising awareness about HS, providing education, and advocating for better treatment options. Their efforts have led to increased visibility of the condition, encouraging more individuals to seek diagnosis and treatment. Furthermore, these groups often collaborate with healthcare professionals and pharmaceutical companies to promote research and development initiatives. The presence of such advocacy is likely to drive demand for innovative therapies and improve patient access to care. As the community continues to grow, it may influence policy changes and funding allocations, ultimately benefiting the Hidradenitis Suppurativa Market by fostering a more supportive environment for patients.

### Increasing Prevalence of Hidradenitis Suppurativa

The rising prevalence of Hidradenitis Suppurativa Market (HS) is a notable driver in the Hidradenitis Suppurativa Market. Recent estimates suggest that HS affects approximately 1-4% of the population, with a higher incidence observed in women and individuals aged 20-40. This increasing prevalence is likely to lead to a greater demand for effective treatment options, thereby expanding the market. As awareness grows, more patients are seeking medical attention, which could further contribute to the market's growth. The need for specialized care and management strategies for HS patients is becoming increasingly recognized, indicating a shift in healthcare focus towards this condition. Consequently, the Hidradenitis Suppurativa Market is poised for expansion as healthcare providers adapt to meet the needs of this growing patient population.

## Future Outlook

The Hidradenitis Suppurativa Market is projected to grow at a 4.72% CAGR from 2025 to 2035, driven by increasing awareness, innovative therapies, and enhanced patient management solutions.

**New opportunities:**

- Development of telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905).
- 
- Investment in biologics and targeted therapies for treatment.
- Expansion of patient education programs to improve treatment adherence.

By 2035, the Hidradenitis Suppurativa Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Skin Conditions: Pimples (Largest) vs. Folliculitis (Fastest-Growing)

In the Hidradenitis Suppurativa Market, the segment of skin conditions encompasses various manifestations, with pimples being the largest contributor to market share, supporting broader hidradenitis suppurativa market analysis insights. This segment reflects a significant portion of patients suffering from hidradenitis suppurativa, where pimples represent a predominant clinical challenge. In contrast, [folliculitis](https://www.marketresearchfuture.com/reports/folliculitis-market-3823), though smaller in share, is rapidly gaining attention due to its emerging prevalence among patients and recognition of its role in exacerbating conditions associated with hidradenitis suppurativa. The growth trends in this segment are driven by increasing awareness and advancements in treatment options. Dermatology practices are focusing more on conditions like folliculitis, leading to improved patient outcomes and growing demand for specific therapies. Additionally, the rise in social media discussions surrounding skin-related issues is prompting patients to seek medical attention sooner, further enhancing the market for both dominant and emerging skin conditions like pimples and folliculitis.

Pimples (Dominant) vs. Boils (Emerging)

Pimples remain the dominant segment in the Hidradenitis Suppurativa Market due to their frequent occurrence and the significant discomfort they cause patients, contributing to the overall hidradenitis suppurativa market size expansion. Characterized by inflamed, pus-filled bumps, pimples are often associated with secondary infections and recurrence, prompting a need for effective treatments. As awareness of hidradenitis suppurativa increases, so does the focus on addressing pimples through targeted therapies. On the other hand, boils are emerging as a notable segment due to their severe manifestations, which can lead to complications if not treated promptly. Though currently less common, their rising incidence is capturing the attention of dermatology practitioners, leading to innovative treatment protocols that cater specifically to this condition, paralleling the interest and resources allocated towards managing pimples.

### By Treatment: Medications (Largest) vs. Surgery (Fastest-Growing)

In the Hidradenitis Suppurativa Market, the treatment segment is primarily divided into medications and surgery. Medications currently hold the largest market share due to their widespread usage and ongoing development in pharmacotherapy options, especially biologics and targeted therapies driving the hidradenitis suppurativa therapeutics market. This segment encompasses both systemic and topical treatments, allowing for personalized management approaches that meet diverse patient needs. On the other hand, surgical interventions are gaining traction, appealing particularly to patients with severe cases of hidradenitis suppurativa that do not respond sufficiently to medical therapy. This growing acceptance of surgical solutions indicates a shift in treatment paradigms within this market.

Surgery: Surgical Interventions (Dominant) vs. Drug Therapy (Emerging)

The treatment landscape for hidradenitis suppurativa is being shaped by two primary approaches: surgical interventions and drug therapy. Surgical interventions, often viewed as a last resort for patients with refractory disease, are emerging as the dominant solution due to their potential for long-term disease control and symptom relief. This shift is driving innovations in minimally invasive techniques and personalized surgical plans. On the other hand, drug therapy is still relevant and is characterized by continuous improvements in medication formulations and delivery methods. As new biological treatments are introduced, drug therapy is emerging as a pragmatic alternative for patients early in their disease course, supporting broader hidradenitis suppurativa market growth analysis trends.

## Regional Market Share Analysis

### North America : Leading Market for Treatments

North America is the largest market for Hidradenitis Suppurativa Market (HS), accounting for approximately 45% of the global hidradenitis suppurativa market share. The region's growth is driven by increasing awareness, advanced healthcare infrastructure, and a rising prevalence of HS, contributing to sustained hidradenitis suppurativa market growth. Regulatory support, including expedited approval processes for new therapies, further catalyzes market expansion. The U.S. is the primary contributor, with significant investments in research and development fueling innovation in treatment options. The competitive landscape in North America is robust, featuring key players such as AbbVie, Amgen, and Janssen Pharmaceuticals. These companies are actively engaged in developing novel therapies, enhancing patient access to effective treatments. The presence of established healthcare systems and a focus on patient-centric care contribute to the region's leadership in the HS market. Continuous collaboration between pharmaceutical companies and healthcare providers is expected to drive further advancements in treatment options.

### Europe : Emerging Market with Potential

Europe is an emerging powerhouse in the Hidradenitis Suppurativa Market, holding approximately 30% of the global market share and driving further hidradenitis suppurativa market analysis insights through innovation and regulatory support. The region's growth is propelled by increasing healthcare expenditure, a rising number of diagnosed cases, and supportive regulatory frameworks. Countries like Germany and France are leading the charge, with initiatives aimed at improving patient outcomes and access to innovative therapies. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new treatments, enhancing market dynamics. Leading countries in Europe include Germany, France, and the UK, where key players such as Novartis and Boehringer Ingelheim are actively involved. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to address the unmet needs of HS patients. Collaborative efforts between stakeholders are essential for advancing research and improving treatment protocols across the region.

### Asia-Pacific : Rapidly Evolving Market Dynamics

The Asia-Pacific region is witnessing rapid growth in the Hidradenitis Suppurativa Market, driven by increasing awareness, rising healthcare investments, and expanding adoption of advanced therapies including biologics for hs. This growth is driven by increasing awareness of HS, rising healthcare investments, and a growing patient population. Countries like Japan and Australia are at the forefront, with initiatives aimed at enhancing diagnosis and treatment options. Regulatory bodies are increasingly focusing on streamlining approval processes for new therapies, which is expected to further boost market growth. In the competitive landscape, key players such as Eli Lilly and Company and GSK are making significant strides in the region. The presence of these companies, along with local firms, is fostering innovation and improving access to treatments. As healthcare systems evolve, the focus on patient-centric care is becoming more pronounced, leading to better management of HS and improved patient outcomes across Asia-Pacific.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa (MEA) region represents an untapped market for Hidradenitis Suppurativa Market, presenting future opportunities aligned with overall hidradenitis suppurativa market growth and therapy adoption. The growth in this region is driven by increasing healthcare investments, a rising prevalence of chronic skin conditions, and a growing awareness of HS. Countries like South Africa and the UAE are beginning to implement healthcare reforms aimed at improving access to treatments and enhancing patient care. Regulatory bodies are also working towards establishing frameworks that support the introduction of new therapies. The competitive landscape in MEA is still developing, with a mix of local and international players entering the market. Companies are focusing on building partnerships with healthcare providers to improve treatment access and patient education. As the region continues to evolve, there is significant potential for growth, particularly in expanding treatment options and increasing awareness among healthcare professionals and patients alike.

## Competitive Benchmarking

The Hidradenitis Suppurativa Market is characterized by a complex competitive landscape driven by innovation, R&D investments, and advancements in biologic treatments, reinforcing broader hidradenitis suppurativa market analysis and competitive positioning.. Key players such as AbbVie (US), Amgen (US), and Janssen Pharmaceuticals (US) are actively shaping the market through innovative therapies and strategic partnerships. AbbVie (US) has positioned itself as a leader in the market with its focus on biologics, particularly the recent advancements in its pipeline targeting inflammatory skin diseases. Meanwhile, Amgen (US) emphasizes its commitment to research and development, aiming to expand its portfolio in dermatological conditions, which could enhance its competitive edge. Janssen Pharmaceuticals (US) is also notable for its strategic collaborations aimed at accelerating the development of new therapies, thereby reinforcing its market presence. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes, which are crucial in meeting the rising demand for treatments. The Hidradenitis Suppurativa Market appears to be moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive innovation and set industry standards, thereby shaping the overall market structure.
In August AbbVie (US) announced the initiation of a pivotal Phase 3 clinical trial for its new biologic therapy aimed at Hidradenitis Suppurativa Market. This strategic move underscores AbbVie's commitment to advancing treatment options and potentially solidifying its leadership position in the market. The trial's outcomes could significantly impact the treatment landscape, offering new hope for patients and enhancing AbbVie's competitive advantage.
In September Amgen (US) revealed a partnership with a leading research institution to explore novel therapeutic targets for Hidradenitis Suppurativa Market. This collaboration is indicative of Amgen's strategy to leverage external expertise and accelerate innovation in its product development pipeline. By aligning with academic research, Amgen may enhance its ability to bring cutting-edge therapies to market, thereby strengthening its foothold in the competitive landscape.
In October Janssen Pharmaceuticals (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment regimens for Hidradenitis Suppurativa Market. This initiative reflects Janssen's recognition of the importance of digital transformation in healthcare. By enhancing patient support and education, Janssen is likely to improve treatment outcomes and foster brand loyalty, which could be pivotal in a market where patient experience is increasingly valued.
As of October the competitive trends in the Hidradenitis Suppurativa Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may ultimately enhance patient care and reshape the market dynamics.

## Recent News & Developments

- **Q2 2024: UCB receives FDA approval for BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults** UCB announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX® (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa, marking a significant regulatory milestone for the company’s dermatology portfolio.
- **Q2 2024: Novartis receives European Commission approval for Cosentyx® (secukinumab) for the treatment of hidradenitis suppurativa** Novartis announced that the European Commission approved Cosentyx® (secukinumab) for the treatment of active moderate to severe hidradenitis suppurativa in adults, expanding the drug’s indications in the EU.
- **Q2 2024: AbbVie announces positive Phase 3 results for SKYRIZI® (risankizumab) in hidradenitis suppurativa** AbbVie reported that its Phase 3 clinical trial of SKYRIZI® (risankizumab) in patients with moderate to severe hidradenitis suppurativa met its primary endpoints, supporting future regulatory submissions.
- **Q1 2024: UCB submits Marketing Authorization Application to EMA for bimekizumab for hidradenitis suppurativa** UCB announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for bimekizumab for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q3 2024: Novartis announces FDA acceptance of sBLA for Cosentyx® in hidradenitis suppurativa** Novartis announced that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for Cosentyx® (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q2 2024: InflaRx announces positive topline results from Phase III trial of vilobelimab in hidradenitis suppurativa** InflaRx reported positive topline results from its Phase III trial evaluating vilobelimab in patients with moderate to severe hidradenitis suppurativa, supporting further regulatory discussions.
- **Q2 2024: MoonLake Immunotherapeutics announces positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa** MoonLake Immunotherapeutics announced that its Phase 2 MIRA trial of sonelokimab in moderate to severe hidradenitis suppurativa met its primary and key secondary endpoints.
- **Q1 2024: InflaRx receives FDA Fast Track designation for vilobelimab in hidradenitis suppurativa** InflaRx announced that the U.S. FDA granted Fast Track designation to vilobelimab for the treatment of hidradenitis suppurativa, expediting its development and review.
- **Q2 2024: UCB launches BIMZELX® (bimekizumab) in the U.S. for hidradenitis suppurativa** Following FDA approval, UCB announced the commercial launch of BIMZELX® (bimekizumab) in the United States for adults with moderate to severe hidradenitis suppurativa.
- **Q2 2024: MoonLake Immunotherapeutics raises $400 million in public offering to advance sonelokimab for hidradenitis suppurativa** MoonLake Immunotherapeutics completed a $400 million public offering to fund the continued development and potential commercialization of sonelokimab for hidradenitis suppurativa.

## Report Scope

| MARKET SIZE 2024 | 0.66(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.6912(USD Billion) |
| MARKET SIZE 2035 | 1.096(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Janssen Pharmaceuticals (US), Novartis (CH), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GSK (GB), Sanofi (FR), Pfizer (US) |
| Segments Covered | Skin Conditions, Treatment, Region |
| Key Market Opportunities | Advancements in biologic therapies enhance treatment options in the Hidradenitis Suppurativa Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Hidradenitis Suppurativa market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Hidradenitis Suppurativa in 2035?**
A: The projected market valuation for Hidradenitis Suppurativa in 2035 is 1.096 USD Billion.

**Q: What was the market valuation for Hidradenitis Suppurativa in 2024?**
A: The overall market valuation for Hidradenitis Suppurativa was 0.66 USD Billion in 2024.

**Q: What is the expected CAGR for the Hidradenitis Suppurativa Market from 2025 to 2035?**
A: The expected CAGR for the Hidradenitis Suppurativa Market during the forecast period 2025 - 2035 is 4.72%.

**Q: Which companies are the key players in the Hidradenitis Suppurativa Market?**
A: Key players in the Hidradenitis Suppurativa Market include AbbVie, Amgen, Janssen Pharmaceuticals, Novartis, Boehringer Ingelheim, Eli Lilly and Company, GSK, Sanofi, and Pfizer.

**Q: What are the main segments of the Hidradenitis Suppurativa Market?**
A: The main segments of the Hidradenitis Suppurativa Market include Skin Conditions and Treatment.

**Q: What was the market size for medications in the Hidradenitis Suppurativa Market in 2024?**
A: In 2024, the market size for medications in the Hidradenitis Suppurativa Market was 0.396 USD Billion.

**Q: What is the projected market size for surgeries in the Hidradenitis Suppurativa Market by 2035?**
A: The projected market size for surgeries in the Hidradenitis Suppurativa Market by 2035 is expected to reach 0.462 USD Billion.

**Q: How much did the segment for boils contribute to the Hidradenitis Suppurativa Market in 2024?**
A: The segment for boils contributed 0.29 USD Billion to the Hidradenitis Suppurativa Market in 2024.

**Q: What is the anticipated growth for the deep-acne like cysts and blackheads segment by 2035?**
A: The anticipated growth for the deep-acne like cysts and blackheads segment is projected to reach 0.2 USD Billion by 2035.

**Q: How does the market for folliculitis compare to other skin conditions in 2024?**
A: In 2024, the market for folliculitis was valued at 0.1 USD Billion, indicating a smaller contribution compared to other skin conditions.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hidradenitis-suppurativa-market-3770*